IM Cannabis to Report Second Quarter 2022 Financial Results on Monday, August 15 at 9:00am ET
08/04/2022 - 07:00 AM
TORONTO and GLIL YAM, Israel Aug. 4, 2022 IM Cannabis Corp . (the "Company " or "IM Cannabis ") (CSE: IMCC) (NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel , Canada , and Germany , will report operational and financial results for the second quarter ended June 30, 2022 , on Monday, August 15, 2022 before market opens.
The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here . All relevant information will be sent upon registration.
If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call.
About IM Cannabis Corp.
IM Cannabis (NASDAQ: IMCC) (CSE: IMCC) is a leading international cannabis company providing premium products to medical patients and adult-use recreational consumers. IM Cannabis is one of the very few companies with operations in Israel , Germany , and Canada , the three largest federally legal markets. The ecosystem created through its international operations leverages the Company's unique data-driven perspective and product supply chain globally. With its commitment to responsible growth and financial prudence, and the ability to operate within the strictest regulatory environments, the Company has quickly become one of the leading cultivators and distributors of high-quality cannabis globally.
In Israel , the Company imports and sells premium and ultra-premium medical cannabis, operating retail pharmacies, online platforms, distribution centres and logistical hubs through IMC Holdings Ltd. and its subsidiaries and affiliates, which enable safe delivery and quality control throughout the entire value chain. In Germany , the IM Cannabis ecosystem operates through Adjupharm GmbH, where it also distributes cannabis to pharmacies to medical cannabis patients. In Canada , IM Cannabis operates through Trichome Financial Corp. and its subsidiaries TJAC and MYM, where it cultivates and processes cannabis for the adult-use market at its Ontario , Nova Scotia , and Quebec facilities under the WAGNERS and Highland Grow brands.
Logo - https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
Company Contact:
Maya Lustig , Director Investor & Public Relations
IM Cannabis maya.l@imcannabis.com
https://www.prnewswire.com/news-releases/im-cannabis-to-report-second-quarter-2022-financial-results-on-monday-august-15-at-900am-et-301599797.html
SOURCE IM Cannabis Corp.
IMCC Rankings
N/A Ranked by Stock Gains
IMCC Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
About IMCC
premium medical cannabis products for global consumers – im cannabis (imc) is one of the world's pioneering medical-grade cannabis companies, with operations in israel, across europe, and canada. over the past decade, imc has established its premium medical cannabis brand, comprising a full spectrum of products known for their quality, consistency, and purity, such as 'roma', 'tel aviv' and 'london'. in europe, imc has established a fully operational, vertically integrated medical cannabis business, spearheaded by its eu-gmp certified distribution arm in germany and augmented by strategic alliances with certified pan-eugmp certified suppliers. to this end, imc has formed strong strategic alliances within the international medical cannabis industry, aiming for a dominant position in satisfying the global demand for high-quality medical cannabis products, which both physicians and patients can rely upon. imc further intends to leverage its expertise in israel in order to bolster its res
